Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like Bayer HealthCare Expansion Brings New Jobs to the Bay Area August 16, 2017 Rumors Surface M&A-Desperate Gilead is Nearing a Deal to Buy Incyte March 12, 2017 REGENXBIO Banks on Strong Gene Therapy Pipeline and Potential Partnerships January 8, 2018
